{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:50:27Z","timestamp":1740160227799,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The safety of administration of tirofiban, a\u00a0platelet glycoprotein IIb\/IIIa inhibitor, followed by a\u00a0clopidogrel loading dose in clopidogrel-na\u00efve patients undergoing ad-hoc percutaneous coronary intervention (PCI) is not yet clear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a\u00a0retrospective observational cohort analysis, clopidogrel-na\u00efve patients undergoing ad-hoc PCI who received a\u00a0high-dose bolus of tirofiban (25\u202f\u03bcg\/kg) followed by a\u00a0600-mg clopidogrel loading dose (group\u00a01) were compared with patients undergoing elective PCI who were pretreated with clopidogrel (group\u00a02), between September 2014 and October 2021. The primary outcome was major adverse cardiovascular events (MACE) defined as the composite of death, myocardial infarction, stroke, target-lesion revascularisation and bleeding at 30\u00a0days. Secondary outcomes were MACE at 7\u00a0days and individual components of the primary outcome at 7\u00a0and 30\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A\u00a0total of 1404 patients were included: 432 (31%) in group\u00a01 and 972 (69%) in group\u00a02. Median age was 69\u00a0years, and 28% were female. At 7\u2011day follow-up, MACE occurred in 1.4% in group\u00a01 versus 3.0% in group\u00a02 (<jats:italic>p<\/jats:italic>\u202f=\u20090.08). 30-day MACE were observed in 1.9% in group\u00a01 and 4.2% in group\u00a02 (<jats:italic>p<\/jats:italic>\u202f=\u20090.03). Secondary outcomes were comparable between the groups. Cox regression analysis, corrected for baseline differences, revealed no significant difference in the primary outcome (hazard ratio:\u00a01.8; 95% confidence interval: 0.8\u20133.9).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ad-hoc PCI in clopidogrel-na\u00efve patients who were treated with high-dose bolus of tirofiban followed by a\u00a0clopidogrel loading dose immediately after the procedure appeared to be safe.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-023-01810-2","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T09:06:00Z","timestamp":1694768760000},"page":"426-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelet glycoprotein IIb\/IIIa inhibitor tirofiban in clopidogrel-na\u00efve patients undergoing elective percutaneous coronary intervention"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-7670","authenticated-orcid":false,"given":"Zarina","family":"Habibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Luijkx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben C. G.","family":"Gho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo F.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lex A. W.","family":"Ruiters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mera","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnoud W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Rasoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"1810_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti\u00a0J, Wijns\u00a0W, Saraste\u00a0A, et\u00a0al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"1810_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann\u00a0FJ, Sousa-Uva\u00a0M, Ahlsson\u00a0A, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart\u00a0J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"1810_CR3","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine\u00a0GN, Bates\u00a0ER, Blankenship\u00a0JC, et\u00a0al. 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A\u00a0report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J\u00a0Am Coll Cardiol. 2011;58:e44\u2013e122.","journal-title":"J Am Coll Cardiol"},{"key":"1810_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","volume":"29","author":"P Widimsky","year":"2008","unstructured":"Widimsky\u00a0P, Motovska\u00a0Z, Simek\u00a0S, et al. Clopidogrel pre-treatment in stable angina: for all patients \u3009 6\u202fh before elective coronary angiography or only for angiographically selected patients a\u00a0few minutes before PCI? A\u00a0randomized multicentre trial PRAGUE\u20118. Eur Heart\u00a0J. 2008;29:1495\u2013503.","journal-title":"Eur Heart J"},{"key":"1810_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ahj.2007.11.020","volume":"155","author":"MS Sabatine","year":"2008","unstructured":"Sabatine\u00a0MS, Hamdalla\u00a0HN, Mehta\u00a0SR, et\u00a0al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb\/IIIa inhibitor use. Am Heart\u00a0J. 2008;155:910\u20137.","journal-title":"Am Heart J"},{"key":"1810_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","volume":"42","author":"D Antoniucci","year":"2003","unstructured":"Antoniucci\u00a0D, Rodriguez\u00a0A, Hempel\u00a0A, et\u00a0al. A\u00a0randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J\u00a0Am Coll Cardiol. 2003;42:1879\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"1810_CR7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen\u00a0K, Alpert\u00a0JS, Jaffe\u00a0AS, et\u00a0al. Fourth universal definition of myocardial infarction. J\u00a0Am Coll Cardiol. 2018;72:2231\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1810_CR8","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran\u00a0R, Rao\u00a0SV, Bhatt\u00a0DL, et\u00a0al. Standardized bleeding definitions for cardiovascular clinical trials: a\u00a0consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"1810_CR9","first-page":"194","volume":"21","author":"CW Good","year":"2009","unstructured":"Good\u00a0CW, Blankenship\u00a0JC, Scott\u00a0TD, et\u00a0al. Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. J\u00a0Invasive Cardiol. 2009;21:194\u2013200.","journal-title":"J Invasive Cardiol"},{"key":"1810_CR10","doi-asserted-by":"publisher","first-page":"e012844","DOI":"10.1161\/JAHA.119.012844","volume":"8","author":"MJ Marian","year":"2019","unstructured":"Marian\u00a0MJ, Daya\u00a0AH, Chatterjee\u00a0A, et al. Effects of crushed ticagrelor versus eptifibatide bolus plus copidogrel in troponin-negative acute coronary syndrome patients undergoing percutaneous coronary intervention: a\u00a0randomized clinical trial. J\u00a0Am Heart Assoc. 2019;8:e12844.","journal-title":"J Am Heart Assoc"},{"key":"1810_CR11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0300-8932(09)71028-0","volume":"62","author":"E Santas","year":"2009","unstructured":"Santas\u00a0E, Bodi\u00a0V, Sanchis\u00a0J, et\u00a0al. The left radial approach in daily practice. A\u00a0randomized study comparing femoral and right and left radial approaches. Rev Esp Cardiol. 2009;62:482\u201390.","journal-title":"Rev Esp Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-023-01810-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T13:20:02Z","timestamp":1698326402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-023-01810-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s12471-023-01810-2","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"type":"print","value":"1568-5888"},{"type":"electronic","value":"1876-6250"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.\u00a0Habibi, J.\u00a0Luijkx, B.C.G.\u00a0Gho, M.\u00a0Ilhan, L.F.\u00a0Veenstra, L.A.W.\u00a0Ruiters, M.\u00a0Stein, A.W.J.\u00a0van\u00a0\u2019t Hof and S.\u00a0Rasoul declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}